Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients

Expert Opinion on Biological Therapy

Volumn 9, Issue 8, 2009, Pages 945-949

  Vincenzi, Bruno ^a   Santini, Daniele ^a   Loupakis, Fotios ^b   Addeo, Raffaele ^c   Llimpe, Fabiola L Rojas ^d   Baldi, Giacomo Giulio ^b   Di Fabio, Francesca ^d   Del Prete, Salvatore ^c   Pinto, Carmine ^d   Falcone, Alfredo ^b   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c Ospedale S Giovanni di Dio di Frattamaggiore   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Smoking

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CIGARETTE SMOKING; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SMOKING HABIT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; RISK; SMOKING; TREATMENT OUTCOME;

EID: 67650667527     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903081694     Document Type: Article

References (26)

1. Wiley HS, Shvartsman SY, Lauffenburger DA. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol 2003;13:43-50 (Pubitemid 35453894)
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970 (Pubitemid 32963812)
3. Green MR. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139 (Pubitemid 38637993)
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345 (Pubitemid 38944402)
5. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208 (Pubitemid 41079832)
6. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810 (Pubitemid 46211358)
7. Tsuchihashi Z, Khambata-Ford S, Hanna N, et al. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005;353:208-209 (Pubitemid 41058356)
8. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995
9. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379 (Pubitemid 351171687)
10. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25:3930-3935 (Pubitemid 47477270)
11. Ye YN, Liu ES, Shin VY, et al. The modulating role of nuclear factor-κB in the action of α7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-Methyl-N-nitrosamino)- 1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther 2004;311:123-130 (Pubitemid 39287791)
12. Crowley-Weber CL, Dvorakova K, Crowley C, et al. Nicotine increases oxidative stress, activates NF-κB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate:relevance to colon carcinogenesis. Chem Biol Interact 2003;145:53-66 (Pubitemid 36246610)
13. Ye YN, Liu ES, Shin VY, et al. Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther 2004;308:66-72 (Pubitemid 38090701)
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
15. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39
16. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220
17. Carlisle DL, Liu X, Hopkins TM, et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 2007;20:629-641 (Pubitemid 47446337)
18. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923 (Pubitemid 39665498)
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500 (Pubitemid 38720929)
20. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006;94:896-903
21. van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25:2646-2647 (Pubitemid 47123179)
22. Du B, Altorki NK, Kopelovich L, et al. Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism. Cancer Res 2005;65:5982-5988 (Pubitemid 40911206)
23. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237 (Pubitemid 47325606)
24. Weijenberg MP, Aardening PW, de Kok TM, et al. Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study. Mutat Res 2008;652:54-64
25. Slattery ML, Anderson K. Curtin K, et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001;483: 73-81 (Pubitemid 33000068)
26. Wark PA, Van der Kuil W, Ploemacher J, et al. Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. Int J Cancer 2006;119:398-405 (Pubitemid 43911906)